Despite no major therapeutic trial results in 2020, the landscape of multiple sclerosis (MS) is changing, with better insight on prognosis, entry of artificial intelligence in MS brain imaging, technological advances challenging knowledge on disease pathogenesis, identification of novel therapeutic pathways. But 2020 will certainly be remembered as the year of outbreak